Works matching IS 17762596 AND DT 2023 AND VI 18 AND IP 4

Results: 13

Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 625, doi. 10.1007/s11523-023-00981-7

By:

Zheng, Nan;
Zhang, Yimin;
Zeng, Yue;
Ma, Qiang;
Zhang, Ruiguang;
Zhao, Qian;
Lu, Conghua;
Tian, Jie;
Wang, ZhiGuo;
Tang, Huan;
Luo, Nuo;
Xiao, Hualiang;
He, Yong;
Wu, Fang;
Li, Li

Publication type:

Article

Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case–Control Study.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 601, doi. 10.1007/s11523-023-00980-8

By:

Storm, Erica M.;
Makrakis, Dimitrios;
Lin, Genevieve I.;
Talukder, Rafee;
Bakaloudi, Dimitra R.;
Shah, Eshana E.;
Liou, Iris W.;
Hockenbery, David;
Grivas, Petros;
Khaki, Ali Raza

Publication type:

Article

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 543, doi. 10.1007/s11523-023-00979-1

By:

DeMichele, Angela;
Robert, Nicholas;
Chen, Connie;
Kim, Sindy;
Zhang, Zhe;
Lu, Dongrui Ray;
Aguilar, Kathleen M.;
Wang, Yunfei;
Li, Benjamin;
Schneeweiss, Sebastian;
Rassen, Jeremy A.;
Gaffney, Michael;
McRoy, Lynn

Publication type:

Article

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 559, doi. 10.1007/s11523-023-00978-2

By:

Santoni, Matteo;
Massari, Francesco;
Myint, Zin W.;
Iacovelli, Roberto;
Pichler, Martin;
Basso, Umberto;
Kopecky, Jindrich;
Kucharz, Jakub;
Buti, Sebastiano;
Rizzo, Mimma;
Galli, Luca;
Büttner, Thomas;
De Giorgi, Ugo;
Kanesvaran, Ravindran;
Fiala, Ondřej;
Grande, Enrique;
Zucali, Paolo Andrea;
Fornarini, Giuseppe;
Bourlon, Maria T.;
Scagliarini, Sarah

Publication type:

Article

Correction to: Relugolix: A Review in Advanced Prostate Cancer.

Published in:

2023

By:

Shirley, Matt

Publication type:

Correction Notice

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 585, doi. 10.1007/s11523-023-00976-4

By:

Babey, Hélène;
Jamme, Philippe;
Curcio, Hubert;
Assié, Jean Baptiste;
Veillon, Remi;
Doubre, Hélène;
Pérol, Maurice;
Guisier, Florian;
Huchot, Eric;
Decroisette, Chantal;
Falchero, Lionel;
Corre, Romain;
Cortot, Alexis;
Chouaïd, Christos;
Descourt, Renaud

Publication type:

Article

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 571, doi. 10.1007/s11523-023-00973-7

By:

Wang, Michelle;
Slatter, Shadera;
Sussell, Jesse;
Lin, Chia-Wei;
Ogale, Sarika;
Datta, Debajyoti;
Butte, Atul J.;
Bazhenova, Lyudmila;
Rudrapatna, Vivek A.

Publication type:

Article

Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 611, doi. 10.1007/s11523-023-00974-6

By:

Yen, Chih-Chieh;
Yeh, Yu-Min;
Huang, Hsuan-Yi;
Ting, Yu-Lin;
Fu, Pei-An;
Lin, Tzu-Chien;
Liu, I-Ting;
Yen, Chia-Jui

Publication type:

Article

Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 505, doi. 10.1007/s11523-023-00975-5

By:

Chiu, Chao-Hua;
Lin, Meng-Chih;
Wei, Yu-Feng;
Chang, Gee-Chen;
Su, Wu-Chou;
Hsia, Te-Chun;
Su, Jian;
Wang, Anne Kuei-Fang;
Jen, Min-Hua;
Puri, Tarun;
Shih, Jin-Yuan

Publication type:

Article

Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 593, doi. 10.1007/s11523-023-00972-8

By:

Heseltine, Jonathan;
Allison, Jennifer;
Wong, Sam;
Prasad, Kellati;
Oong, Zhu-Chuen;
Wong, Helen;
Law, Andrea;
Charnley, Natalie;
Parikh, Omi;
Waddell, Tom;
Chow, Shien

Publication type:

Article

PARP Inhibitors in Ovarian Cancer: A Review.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 471, doi. 10.1007/s11523-023-00970-w

By:

O'Malley, David M.;
Krivak, Thomas C.;
Kabil, Nashwa;
Munley, Jiefen;
Moore, Kathleen N.

Publication type:

Article

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 517, doi. 10.1007/s11523-023-00965-7

By:

Bauer, Todd M.;
Moore, Kathleen N.;
Rader, Janet S.;
Simpkins, Fiona;
Mita, Alain C.;
Beck, J. Thaddeus;
Hart, Lowell;
Chu, Quincy;
Oza, Amit;
Tinker, Anna V.;
Imedio, Esteban Rodrigo;
Kumar, Sanjeev;
Mugundu, Ganesh;
Jenkins, Suzanne;
Chmielecki, Juliann;
Jones, Suzanne;
Spigel, David;
Fu, Siqing

Publication type:

Article

Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.

Published in:

Targeted Oncology, 2023, v. 18, n. 4, p. 531, doi. 10.1007/s11523-023-00966-6

By:

Elsea, David;
Muston, Dominic;
Fan, Lin;
Mihai, Adela;
Meng, Yang;
Kasle, Adam;
Monberg, Matthew

Publication type:

Article